medicalxpress.com

medicalxpress.com
Share

medicalxpress.com

 •  November 4

The pharmaceutical company Biogen has today announced the results of an extended phase 1b clinical trial of the potential Alzheimer's disease drug, aducanumab. Results from the extended early stage trial, were announced today at Clinical Trials in Alzheimer's Disease (CTAD) conference in Boston. Aducanumab is an antibody that targets amyloid, a...

medicalxpress.com

 •  September 30

Scientists at The Scripps Research Institute (TSRI) have developed and demonstrated a promising new strategy for the discovery of novel anti-cancer therapies. The TSRI scientists, collaborating with scientists at Pfizer, used their new approach to find small-molecule inhibitors of a protein that is important for the growth of non-small-cell lung...

medicalxpress.com

 •  September 28

(HealthDay)—Long-term treatment with the drug rituximab (Rituxan) may extend the lives of some patients with a rare form of blood cancer, a new clinical trial finds. The disease, known as mantle-cell lymphoma, is generally incurable. But various treatments can prolong people's lives. Some patients, for instance, are able to undergo chemotherapy to...

medicalxpress.com

 •  September 28

According to the National Institute on Drug Abuse, more than 90 Americans die every day by overdosing on opioids. While heroin and synthetic opioids such as fentanyl account for part of the crisis, in 2015 about 2 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers. Now, a recent study from...

medicalxpress.com

 •  September 19

A drug used to treat conditions such as epilepsy has been shown in lab tests at The University of Manchester to significantly improve bone growth impaired by a form of dwarfism. Metaphyseal chondrodysplasia type Schmid (MCDS), is a genetic condition caused by mutations in 'collagen X' which affect cell differentiation and bone growth. The team are...

medicalxpress.com

 •  September 15

Mvasi (bevacizumab-awwb) was found to be biosimilar to the drug Avastin (bevacizumab), the FDA said Thursday in a news release. Avastin was approved in 2004. Mvasi is approved to treat certain colorectal, lung, brain, kidney, and cervical cancers. The most common side effects of Mvasi include epistaxis, headache, hypertension, rhinitis,...

medicalxpress.com

 •  September 15

(HealthDay)—Aliqopa (copanlisib) has been approved by the U.S. Food and Drug Administration to treat adults with relapsed follicular lymphoma who have received at least two prior treatments with certain other drugs. Aliqopa is a kinase inhibitor, designed to block enzymes that spur cancer growth, the FDA explained Thursday in a news release. The...

medicalxpress.com

 •  September 13

Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published in the latest issue of The Lancet Infectious Diseases. The results are significant as public health experts have long warned that the parasite responsible for most...

medicalxpress.com

 •  August 31

A KAIST research team presented a novel method for improving medication treatment for liver cancer using Systems Biology, combining research from information technology and the life sciences. Professor Kwang-Hyun Cho in the Department of Bio and Brain Engineering at KAIST conducted the research in collaboration with Professor Jung-Hwan Yoon in the...

medicalxpress.com

 •  August 23

A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK, through Cancer Research UK's Centre for Drug Development. This early phase trial will test the safety and tolerability of the drug and establish the recommended dose for patients with a variety of cancers including advanced...